Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Quark Pharmaceuticals closes $10M private financing round

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.

10 Jun 2010

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.

9 Jun 2010

NexGen Biomedical offers RNAi / PSR platform technology for sale

NexGen Biomedical, Inc. announced today that it is offering its RNAi / PSR platform technology for sale. "While technologies like siRNA are well suited for disease conditions involving expression of a single protein, the RNAi / PSR technology is better suited for conditions involving expression of a broad spectrum of proteins such as happens with cell hyperproliferation, inflammation, and viral infections.

8 Jun 2010

USPTO grants ISCO patent to International Stem Cell's hpSC

International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

8 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

7 Jun 2010

Researcher calls stroke specialists to further knowledge and understanding of stroke

To cope with the projected growth in the incidence of strokes in Canada, the public may need to take on roles traditionally performed by healthcare specialists, according to a leading Canadian stroke researcher.

7 Jun 2010

Microplasmin exhibits potential to cure 50% of patients with macular hole

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the World Ophthalmology Congress by Dr. Matthew Benz, MD (The Methodist Hospital, Houston, Texas, U.S.)

7 Jun 2010

Top physicians offer health advice to help people survive during summer

This summer a variety of top physicians at NewYork-Presbyterian Hospital are offering health advice to help survive the travails that come with one of the most active seasons of the year.

3 Jun 2010

UCI scientists create eight-layer, early-stage retina from human embryonic stem cells

UC Irvine scientists have created an eight-layer, early-stage retina from human embryonic stem cells, the first three-dimensional tissue structure to be made from stem cells.

27 May 2010

New book to prevent Age-Related Macular Degeneration

A new prevention tool is now available, in both French and English, at local bookstores and pharmacies. Dr. Jean-Daniel Arbour and Dr. Pierre Labelle of the Universit- de Montr-al Department of Ophthalmology, along with two colleagues from France, have authored a new book to prevent vision loss, AMD: Age-Related Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate readers about the importance of vision health, the book provides clear explanations on the causes, consequences and treatments of AMD.

26 May 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL.

19 May 2010

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Four new projects, announced today, will develop biological methods that offer a new approach to antibiotic production, power generation for extremely small mechanical components, new classes of medicines and innovative techniques to study cell biology.

19 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

The Burnier International Ocular Pathology Society is holding a Scientific Colloquium in Montreal today to mark the tenth anniversary of the McGill University Health Centre's Henry C. Witelson Ocular Pathology Laboratory. The lab is an internationally reputed centre for the study and treatment of eye diseases and is leading a global network for the sharing of healthcare knowledge and expertise.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale.

7 May 2010

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the presentation of a poster at the 2010 American Transplant Congress titled, "A Nomogram for Predicting Risk of Delayed Graft Function Following Machine Perfusion of Renal Transplants."

5 May 2010

StemCells first-quarter total revenue up 307%

StemCells, Inc., a leading stem cell technology company with the dual focus of novel therapeutics and innovative research products, today reported financial results for the first quarter ended March 31, 2010 and recent business highlights.

5 May 2010

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome™ Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.

5 May 2010

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Quark Pharmaceuticals closes $10M private financing round

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

NexGen Biomedical offers RNAi / PSR platform technology for sale

USPTO grants ISCO patent to International Stem Cell's hpSC

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Researcher calls stroke specialists to further knowledge and understanding of stroke

Microplasmin exhibits potential to cure 50% of patients with macular hole

Top physicians offer health advice to help people survive during summer

UCI scientists create eight-layer, early-stage retina from human embryonic stem cells

New book to prevent Age-Related Macular Degeneration

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

StemCells first-quarter total revenue up 307%

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in